Synchrony Financial SYNCHRONY FIN.../ US87165B1035 /
2024-05-03 2:12:53 PM | Chg. - | Volume | Bid6:00:05 AM | Ask6:00:05 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
45.00USD | - | 504,373 Turnover: 22.6 mill. |
-Bid Size: - | -Ask Size: - | 20.07 bill.USD | 1.95% | 9.47 |
GlobeNewswire
06-13
What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...
GlobeNewswire
06-11
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patie...
GlobeNewswire
06-08
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2...
GlobeNewswire
05-23
AI-Based Analysis of Dynamic Digital Radiography Data Gives Researchers Greater Insight into Lung Fu...
GlobeNewswire
05-10
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
GlobeNewswire
04-23
Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9
GlobeNewswire
04-04
100 Best Companies to Work For in 2024 Deliver ‘Staggering’ Business Performance
GlobeNewswire
03-08
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwr...
GlobeNewswire
03-07
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenter...
GlobeNewswire
03-04
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2...
GlobeNewswire
02-29
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efru...
GlobeNewswire
02-29
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business...
GlobeNewswire
01-03
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-29
Visionary Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its ...
GlobeNewswire
2023-12-18
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
GlobeNewswire
2023-11-13
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-11-10
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Live...
GlobeNewswire
2023-11-08
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November